Abstract:OBJECTIVE To make a comparison of sensitivity and specificity between serum miR-122 and traditional biomarkers of drug-induced liver injury. METHODS Acetaminophen (APAP, 1250 mg · kg-1, ig), α-naphthylisothiocyanate (ANIT, 150 mg · kg-1, ig), methionine-choline deficient diet (MCDD, free feeding) and carbon tetrachloride (CCl4, 50%, ip) were used to establish hepatocellular injury, cholestasis, steatosis and fibrosis models, respectively, which were used to evaluate the sensitivity of serum miR-122 as a biomarker of drug-induced liver injury, when compared with the traditional biomarkers. Isoprenaline hydrochloride (IH) and gentamicin (GM) were used to establish myocardial and renal injury models, respectively, which were used to evaluate the specificity of serum miR-122, when compared with the tradi-tional biomarkers. Serum and liver tissues were collected at different time points during the study. Tradi-tional biomarkers such as glutamic-pyruvic transaminase (GPT), glutamic-oxaloacetic transaminase (GOT) and total bilirubin (TBIL) were measured with an automatic biochemistry analyzer. MiR-122 was detected with real- time quantitative PCR. Histopathological examination with HE staining was performed for liver tissues. RESULTS Serum miR-122 increased significantly earlier [miR-122 was signifi-cantly increased (>2 fold) at 1.5 h, 3 h, 2 weeks and 4 weeks after treatment in the four models respec-tively, while no significant increase (<2 fold) was observed for GPT, GOT and TBIL at 6 h, 12 h, 3 weeks and 6 weeks after treatment in the four models respectively] and more signficantly (the maximum fold change for miR-122 was 235.8, 202.7, 73.8 and 600.3 for the four models, respectively. For the GPT, the maximum fold change was 9.5, 3.9, 2.5 and 6.6, respectively; 6.0, 2.4, 1.4 and 3.5 respectively for GOT; 2.6, 2.3, 1.2 and 1.8 respectively for TBIL) than that of traditional biomarkers in hepatocellular injury, cholestasis, steatosis and fibrosis models, when compared with the control group. In the myocar-dial injury model, a significant increase of GOT was observed after IH treatment (2.1 fold), while no change was observed for serum miR-122. In the renal injury model, no false positive results were observed for serum miR-122. CONCLUSION Serum miR-122 can be used as a biomarker of drug-induced liver injury and serum miR-122 is more sensitive and specific than traditional biomarkers (such as GPT, GOT and TBIL).

Sensitive detection of human drug-induced liver injury by measurement of microRNA-122 using single molecule arrays

Amplification-free electrochemical biosensor detection of circulating microRNA to identify drug-induced liver injury

Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics

Ultrasensitive Upconverting Nanoprobes for in Situ Imaging of Drug-Induced Liver Injury Using Mir-122 As the Biomarker

Multiplex Profiling of miR-122 for Preclinical and Clinical Evaluation of Drug-Induced Liver Injury by a Full-Scale Platform

Highly Sensitive and Label-Free Detection of DILI Microrna Biomarker Via Target Recycling and Primer Exchange Reaction Amplifications.

A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry

A Sensitive Upconverting Nanoprobe Based on Signal Amplification Technology for Real-Time in Situ Monitoring of Drug-Induced Liver Injury

Serum microRNA‐122 for assessment of acute liver injury in patients with extensive skeletal muscle damage

miR122-controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-demand drug release

MicroRNAs in Drug-induced Liver Injury.

A Panel Of Serum Micrornas As Specific Biomarkers For Diagnosis Of Compound- And Herb-Induced Liver Injury In Rats

Isothermal and Enzyme-free MicroRNA Assay Based on Catalytic Hairpin Assembly and Rare Earth Element Labeled Probes

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Comparison on sensitivity and specificity of serum miR-122 as biomarkers of drug-induced liver injury

Click Chemistry-Driven Dual Nanosystem for miR-122 Detection with Single-Base Specificity from Tumour Cells

Circulating Microrna-122 As a Potential Biomarker for Liver Injury

Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis

Development of a Modular miRNA-Responsive Biosensor for Organ-Specific Evaluation of Liver Injury

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

An Extracellular Mirna‐responsive Artificial Receptor Via Dynamic DNA Nano‐assembly for Biomarker‐Driven Therapy